Abstract
Recent evidence has led us to propose that transforming growth factor-β (TGF-β) is a key inhibitor of atherosclerosis. We show here that a population of patients with advanced atherosclerosis all have less active TGF-β in their sera than patients with normal coronary arteries, with a fivefold difference in average concentration between the two groups. This correlation with atherosclerosis is much stronger than for other Known major risk factors and it may therefore have important diagnostic and prognostic significance. Aspirin medication correlates with an increase in active TGF-β concentration, indicating that therapeutic interventions for TGF-β are possible.
This is a preview of subscription content, access via your institution
Access options
Similar content being viewed by others
References
Syetkowski, P.A. et al. Changes in risk factors and the decline in mortality from cardiovascular disease: the Framingham study. New. Engl J. Med. 322, 1635–1641 (1990).
Utermann, G. The mysteries of lipoprotein (a). Science 246, 904–910 (1989).
Genest, J.J. et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 85, 2025–2033 (1992).
Schreiner, P.J. et al. Lipoprotein (a) as a risk factor for preclinical atherosclerosis. Arterioscl Thromb. 13, 826–833 (1993).
Wald, N.J. et al. Apolipoproteins and ischaemic heart disease — implications for screening. The Lancet 343, 75–79 (1994).
Law, M.R. et al. Assessing possible hazards of reducing serum cholesterol. Br. med. J. 308, 373–379 (1994).
Hamsten, A. et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. New. Engl. J. Med. 313, 1557–1563 (1985).
de Bono, D. Significance of raised plasma concentrations of tissue type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br. Heart J. 71, 504–507 (1994).
Gordon, D.J. & Rifkind, B.M. Current concepts-high density lipoprotein — the clinical implications of recent studies. New. Engl. J. Med. 321, 1311–1316 (1989).
Kannel, W.B. High density lipoproteins: epidemiological profile and risks of coronary artery disease. Am. J. Cardiol 52, 9–12B (1983.
Grainger, D.J. et al. Proliferation of human smooth muscle Cells promoted by lipoprotein (a). Science 260, 1655–1658 (1993).
Grainger, D.J. et al. Activation of transforming growth factor b is inhibited in apolipoprotein (a) transgenic mice. Nature 370, 460–462 (1994).
Ross, R. & Glomset, J.N. The pathogenesis of atherorosclerosis. N. Eng. J. Med. 295, 369–377 (1976).
Ross, R. The pathogenesis of atherosclerosis : a perspective for the 1990s. Nature 362, 801–809 (1993.
Kojima, S., Harpel, P.C. & Rifkin, D.B. Lipoprotein (a) inhibits the generation of transforming growth factor b: an endogenenous inhibitor of smooth muscle Cell migration. J. cell Biol. 113, 1439–1443 (1991).
Kirschenlohr, H.L. et al. Adult human aortic smooth muscle Cells in culture produce active TGF-β. Am. J. Physiol 265, C571–C576 (1993).
Lyons, R., Keski-Oja, J. & Moses, H.L. Proteolytic activation of latent transforming growth factor-β from fibroblast conditioned medium. J. Cell Biol. 106, 1659–1665 (1988).
Lyons, R.M. et al. Mechanisms of activation of latent recombinant transforming growth factor β by plasmin. J. Cell Biol. 110, 1361–1367 (1990).
McLean, J.W. et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 330, 132–137 (1987).
Lawrence, D.A. Identification and activation of latent transforming growth factor β. Meth Enzym 198, 327–336 (1991).
Grainger, D. et al. Active and acid-activatable TGF-b in human sera, platelets and plasma. Clin. Chim. Acta (In the press).
McDonald, C.C. & Stewart, H.J. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br. med. J. 303, 435–437 (1991).
Colletta, A.A. et al. Antioestrogens induce the secretion of active transforming growth factor-β from foetal human fibroblasts. Br. J. Cancer 62, 405–409 (1990).
Grainger, D.J. et al. decreases the rate of proliferation of rat vascular smooth muscle cells in culture by inducing the production of transforming growth factor-β. Biochem. J. 294, 109–112 (1993).
Butta, A. et al. Induction of transforming growth factor-β in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 52, 4261–4264 (1992).
Lin, H.Y. et al. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell 68, 775–786 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grainger, D., Kemp, P., Metcalfe, J. et al. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med 1, 74–79 (1995). https://doi.org/10.1038/nm0195-74
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0195-74
This article is cited by
-
Cell-free ascites from ovarian cancer patients induces Warburg metabolism and cell proliferation through TGFβ-ERK signaling
GeroScience (2024)
-
Transforming growth factor beta 1 is associated with subclinical carotid atherosclerosis in patients with systemic lupus erythematosus
Arthritis Research & Therapy (2023)
-
Factors Influencing Collateral Circulation Formation After Indirect Revascularization for Moyamoya Disease: a Narrative Review
Translational Stroke Research (2023)
-
Angiogenic content of microparticles in patients with diabetes and coronary artery disease predicts networks of endothelial dysfunction
Cardiovascular Diabetology (2022)
-
Stable CAD patients show higher levels of platelet-borne TGF-β1 associated with a superior pro-inflammatory state than the pro-aggregatory status; Evidence highlighting the importance of platelet-derived TGF-β1 in atherosclerosis
Journal of Thrombosis and Thrombolysis (2022)